LYEL - Lyell Immunopharma Inc
22.46
0.410 1.825%
Share volume: 42,370
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.20%
PREVIOUS CLOSE
CHG
CHG%
$22.05
0.41
0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | |
| Report Date | 05-06-2024 | 08-07-2024 | 11-07-2024 | 03-11-2025 | 05-13-2025 | 11-12-2025 | |
| Total revenue | 3.000 K | 13.000 K | 34.000 K | 11.000 K | 7.000 K | 15.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 3.000 K | 13.000 K | 34.000 K | 11.000 K | 7.000 K | 15.000 K | |
| 333.33% | 161.54% | -67.65% | -36.36% | 114.29% | |||
| Operating expenses | 56.668 M | 52.517 M | 51.269 M | 150.374 M | 57.493 M | 38.859 M | |
| Selling general and admin | 13.494 M | 12.256 M | 11.769 M | 14.522 M | 14.046 M | 10.687 M | |
| Research and development | 43.174 M | 40.261 M | 39.500 M | 135.852 M | 43.447 M | 28.172 M | |
| Total expenses | 55.578 M | 51.541 M | 50.539 M | 201.158 M | 57.374 M | 37.268 M | |
| -7.26% | -1.94% | 298.03% | -71.48% | -35.04% | |||
| Operating income | -55.575 M | -51.528 M | -50.505 M | -201.147 M | -57.367 M | -37.253 M | |
| Ebit | -67.486 M | -52.173 M | -50.548 M | -201.549 M | -56.057 M | -42.112 M | |
| Pretax income | -60.667 M | -45.809 M | -44.583 M | -196.629 M | -52.195 M | -38.846 M | |
| -24.49% | -2.68% | 341.04% | -73.46% | -25.58% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -60.667 M | -45.809 M | -44.583 M | -191.935 M | -52.195 M | -38.846 M | |
| 24.49% | 2.68% | -330.51% | 72.81% | 25.58% |